Pantethine Plus Standard Ointment Eased Psoriasis in 24-Patient Trial

A 12-week trial in 24 psoriasis patients found that adding oral pantethine, a vitamin B5 derivative sold as a cholesterol-lowering supplement, to standard topical calcipotriol/betamethasone dipropionate improved symptoms. Researchers at the State Key Laboratory of Biomedical Analysis (SKLBA) in Beijing reported the results in the Journal of Experimental Medicine, alongside mouse data showing that pantethine prevented psoriasis from developing at all.

Senior author Wei-Na Zhang, PhD, and co-leads Qing Xia, PhD, Ai-Ling Li, PhD, and Tao Zhou, PhD, all of SKLBA, together with Cheng-Xin Li, PhD, of The First Medical Center of Chinese PLA General Hospital in Beijing, framed the work as a metabolic intervention aimed at dendritic cells. The authors wrote that their findings point to "a potentially viable metabolic strategy for DC-centered intervention in AIDs [autoimmune diseases]."

What did the mechanistic work show?

Dendritic cells present antigens to T cells and secrete inflammatory signaling molecules. Abnormal activation of these cells is thought to drive psoriasis and other autoimmune conditions. The team found that levels of metabolic enzymes called Vanins are elevated in dendritic cells from psoriasis patients and from patients with several other autoimmune diseases.

Vanins convert pantethine into vitamin B5, an essential nutrient for cellular energy production. The researchers showed that increased Vanin activity lowers pantethine levels, which raises cholesterol synthesis and drives dendritic cells into hyperactivation. Cholesterol itself can promote dendritic cell activation, and high blood cholesterol is a known risk factor for psoriasis.

Depleting Vanin enzymes inhibited dendritic cell activation and reduced the cells' ability to activate T cells. Mice treated with a drug that inhibits Vanins did not develop psoriasis. Replenishing pantethine reversed the process in the same way, cutting cholesterol accumulation. "Pantethine supplementation or pharmacologically induced Vanin inhibition reduces cholesterol overload, impedes DC activation, and mitigates psoriasiform inflammation," the authors wrote.

Zhang noted: "We found that pantethine administration effectively alleviated psoriasis in mice, suggesting that insufficient pantethine levels may be the crucial contributor to hyperactivation of dendritic cells and autoimmune inflammation following the upregulation of Vanins."

How strong is the human evidence?

The clinical arm was an investigator-initiated trial of just 24 patients — roughly the size of a single cohort in many early-phase studies. All 24 received the topical ointment; half also took oral pantethine capsules. Over 12 weeks, the pantethine group showed improved symptoms, with the clearest benefit among patients who had elevated blood cholesterol at baseline.

Photographs published with the study show marked symptom improvement in the combination-therapy group after three months. The authors reported that "pantethine combination therapy significantly decelerates the progression of psoriasis in patients."

The trial had no randomization details, control-arm blinding, or effect sizes reported in the published summary, and the mechanism in humans was not directly validated. Zhang herself was explicit on this point: "Our investigator-initiated clinical trial demonstrated encouraging therapeutic efficacy of pantethine as an adjunctive therapy in psoriasis, but these findings should be interpreted as proof-of-concept for clinical feasibility rather than direct mechanistic validation."

Why the metabolism angle matters

The study sits within a broader shift toward targeting immune cell metabolism rather than surface receptors alone. Zhang said that "emerging evidence highlights that metabolic pathways and their associated metabolites play vital roles in regulating immune cell function and autoimmune progression," while conceding that "therapeutic strategies targeting metabolism in inflammatory diseases remain underexplored."

Pantethine is already a widely available nutritional supplement, which lowers the barrier to larger trials but also complicates exclusivity for any sponsor. Whether the effect holds at scale, and whether Vanin inhibition can match supplementation, remain open questions. Zhang said the work "provides a foundation for therapeutic strategies targeting several dendritic cell–mediated autoimmune diseases," and larger controlled trials will determine whether a low-cost supplement can earn a place in psoriasis regimens.